travelinglight/iStock through Getty Pictures
Cassava Science (NASDAQ: SAVA) introduced Wednesday that its lead candidate simufil slowed cognitive decline by 38% in comparison with a placebo in a small proof-of-concept research in sufferers with delicate to average Alzheimer’s illness.
The research, which is being carried out within the US, known as the Cognition Upkeep Research (CMS). 157 members who obtained 12 months of oral simufilam therapy in an open-label section after which obtained 100 mg simufilam or placebo for six months.
In keeping with top-line knowledge at six months, these taking simufil had a 0.9-point discount in ADAS-Cog, a medical measure for assessing the extent of Alzheimer’s illness. In the meantime, these taking placebo noticed a 1.5-point discount in ADAS-Cog.
5% or extra of topics reported no treatment-emergent hostile occasions, and the twice-daily research drug was protected and well-tolerated, the corporate mentioned.
Cassava (SAVA) is selling simufil in two giant world section 3 medical trials in about 1,750 sufferers with delicate to average Alzheimer’s illness. The corporate plans to finish enrollment for each trials by the top of 2023.
Extra about simufilam
- Cassava Sciences falls 17% after reporting interim knowledge for Alzheimer’s candidate
- The mechanism of Simufilam by Cassava Sciences is confirmed
